One of the most interesting arguments in modern asthma care isn’t about whether inhaled steroids work—it’s about how patients use them. Personally, I think the INFORM ASTHMA trial matters because it tackles a messy real-world question: what happens when people already on maintenance inhaled corticosteroids still reach for a “reliever,” and that reliever could either be purely bronchodilating or also anti-inflammatory.
We all know asthma isn’t just about tightening airways; it’s about persistent inflammation that quietly keeps the disease simmering underneath. What makes this particularly fascinating is that the trial compares two reliever strategies in adults who already take a controller (budesonide), yet still show markers of type 2 inflammation. In my opinion, this is where the biggest clinical and cultural misunderstanding lives: people often treat the reliever as a separate “emergency tool,” when in reality, frequent reliever use can be a symptom of inadequate suppression of the underlying inflammatory process.
Reliever choice as a hidden driver
The trial looked at adults with mild-to-moderate asthma who were already using maintenance budesonide and who had evidence of airway inflammation measured by FeNO (fractional exhaled nitric oxide) at screening. Patients were randomized to receive either budesonide–formoterol as their reliever or terbutaline as their reliever. The goal wasn’t simply symptom relief in the moment; it was to see how much each reliever approach reduced type 2 airway inflammation over time, especially by week 26.
What many people don’t realize is that reliever use isn’t morally “good” or “bad”—it’s informational. If someone needs reliever medication repeatedly, it may reflect incomplete control, ongoing inflammation, or both. From my perspective, the deeper question is whether we’re designing treatment plans around physiology or around habit.
I also find it telling that the researchers set up the study to address gaps in the evidence base, particularly because randomized controlled trials in patients already on maintenance inhaled corticosteroids haven’t been as plentiful as clinicians would ideally want. Personally, I think this is how medicine progresses: not with grand breakthroughs, but with better-fitting trials that mirror how real patients actually behave.
FeNO results: the signal that can’t be ignored
The primary endpoint was FeNO at week 26, using an intention-to-treat approach. Budesonide–formoterol produced a larger reduction in FeNO compared with terbutaline—reported as an 18.5% greater reduction in geometric mean FeNO at week 26, with statistical significance.
This is where I’d encourage people to slow down and interpret what FeNO represents. FeNO is often treated like a niche biomarker, but conceptually it’s a way of measuring whether type 2 inflammation is still active. In my opinion, the practical implication is that anti-inflammatory reliever strategies may not just “feel better,” they may actually change the inflammatory trajectory of the disease.
A detail that I find especially interesting is that both groups received the same maintenance therapy (budesonide 200 μg). That means the difference is driven largely by the reliever component. If the reliever can influence a marker of inflammation even when the controller is already in place, that challenges a lot of how patients and providers mentally separate “controller time” from “reliever time.”
If you take a step back and think about it, this becomes a critique of compartmentalized care. We often partition asthma management into “daily prevention” and “as-needed rescue,” but the biology doesn’t respect those labels. What this really suggests is that asthma is better managed as a continuous inflammatory process rather than a set of disconnected episodes.
Safety signals and the politics of acceptance
Adverse event rates were similar between groups, with no deaths reported. From a clinician-facing perspective, comparable safety is not just comforting—it’s essential for adoption. Personally, I think one reason anti-inflammatory reliever strategies haven’t always swept the market faster is less about whether they work and more about whether prescribers feel confident recommending them broadly.
There’s also a psychological element. If a therapy asks patients to break from the traditional “reliever = fast bronchodilator” mindset, it can trigger resistance—especially among people who prefer simplicity. In my opinion, the most significant barrier isn’t scientific uncertainty; it’s inertia.
What makes this particularly interesting is how the trial design supports the argument. An open-label randomized parallel-group study can feel less glamorous than a double-blind experiment, but the clinical question here is so behavior-linked that pragmatic design can actually be a strength. People use inhalers in imperfect ways; if outcomes still move in the right direction, that tells a more compelling story about real-world effectiveness.
Why this matters beyond one trial
I see this trial as part of a broader shift toward “single inhaler” logic—where treatment is more integrated, and patients don’t have to navigate multiple roles for multiple devices. Personally, I think the appeal is obvious: asthma management already asks too much from patients, and any strategy that reduces cognitive load can improve adherence.
But here’s the nuance. A regimen that targets inflammation through the reliever could also change how patients interpret their own symptoms. If someone feels fine, they might use fewer reliever doses, and that can further reduce inflammation. Conversely, if symptoms flare, the reliever itself delivers an anti-inflammatory component, potentially softening the next “inflammation wave.”
This raises a deeper question that many people don’t realize is central to asthma outcomes: how often are treatment plans judged by symptom relief rather than by underlying disease activity? Symptoms are important, but FeNO and inflammation measures represent what’s happening when symptoms temporarily quiet down. Personally, I think good care aims to prevent symptoms, not merely patch them.
The trend: moving from episodic to mechanistic control
A detail that stands out is the study’s focus on type 2 airway inflammation, aligning the intervention with modern asthma phenotyping. In my view, this is where the conversation is headed globally: treat asthma not just as a generic lung condition, but as a set of immunologic patterns that respond differently.
From my perspective, the likely future development is more treatment personalization and more insistence on measuring the right outcomes. If FeNO reductions track with better long-term control and fewer exacerbations—as many clinicians hope—then inflammation markers will become less optional and more standard.
At the same time, I think we should be careful not to overpromise. FeNO is a useful compass, not a complete map. Some patients may have inflammation driven by mechanisms not captured well by FeNO alone, and others may respond differently depending on adherence, inhaler technique, comorbidities, or viral triggers. The biological world is more complicated than any single biomarker.
My takeaway: relievers are no longer “just relievers”
Personally, I think the most important takeaway from INFORM ASTHMA is philosophical: it supports the idea that the reliever phase of asthma care should not be purely reactive. If budesonide–formoterol relievers reduce type 2 inflammation more than terbutaline relievers in patients already on maintenance corticosteroids, then the “reliever-only” worldview is outdated.
In my opinion, this doesn’t just change prescriptions; it changes expectations. Patients and clinicians should treat asthma management as an ongoing inflammatory negotiation, not a series of alarms followed by temporary silence. And if we want fewer exacerbations and steadier control, we should design inhalers—and plans—around the disease that persists when nobody is coughing.
Would you like this article to lean more toward a patient-friendly explanation (simpler language) or a clinician-style commentary (more mechanism and guideline implications)?
